Article
Targeting BRAF for patients with melanoma.
British journal of cancer - 1 Feb 2011
Arkenau H-T, Kefford R, Long G V
Abstract excerpt
The prognosis of patients with metastatic melanoma is poor and not influenced by systemic therapy with cytotoxic drugs. New targeted agents directed against the RAS-RAF-MEK-ERK pathway show promising activity in early clinical development and particular interest is focused on selective inhibitors of mutant BRAF, which is present in one half of the cases of metastatic melanoma. The majority of patients on early...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.